Wed, August 2, 2023
Tue, August 1, 2023
Mon, July 31, 2023

Andreas Argyrides Maintained (BMRN) at Hold with Decreased Target to $70 on, Aug 1st, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. with-decreased-target-to-70-on-aug-1st-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Andreas Argyrides of Wedbush, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Hold with Decreased Target from $73 to $70 on, Aug 1st, 2023.

Andreas has made no other calls on BMRN in the last 4 months.



There are 10 other peers that have a rating on BMRN. Out of the 10 peers that are also analyzing BMRN, 3 agree with Andreas's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • George Farmer of "Scotiabank" Initiated at Hold and Held Target at $95 on, Thursday, July 27th, 2023
  • Whitney Ijem of "Canaccord Genuity" Maintained at Hold with Decreased Target to $104 on, Monday, July 3rd, 2023
  • David Lebowitz of "Citigroup" Maintained at Hold with Decreased Target to $96 on, Friday, June 30th, 2023


These are the ratings of the 7 analyists that currently disagree with Andreas


  • Geoff Meacham of "B of A Securities" Maintained at Strong Buy with Decreased Target to $185 on, Friday, July 21st, 2023
  • Kostas Biliouris of "BMO Capital" Upgraded from Hold to Buy and Held Target at $102 on, Wednesday, July 5th, 2023
  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Increased Target to $140 on, Friday, June 30th, 2023
  • Joel Beatty of "Baird" Reiterated at Buy and Held Target at $127 on, Friday, June 30th, 2023
  • Tiago Fauth of "Credit Suisse" Initiated at Buy and Held Target at $120 on, Wednesday, June 14th, 2023
  • Debjit Chattopadhyay of "Guggenheim" Maintained at Strong Buy with Decreased Target to $120 on, Thursday, April 27th, 2023
  • Christopher Raymond of "Piper Sandler" Maintained at Buy with Decreased Target to $125 on, Thursday, April 27th, 2023

Publication Contributing Sources